Tag: neurodegenerative disorders
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More
Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in ... Read More
Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative ... Read More